Last Price
16.50
Today's Change
+2.10 (14.58%)
Day's Change
14.60 - 16.54
Trading Volume
1,009,792
Market Cap
2 Billion
Shares Outstanding
127 Million
Avg Volume
521,765
Avg Price (50 Days)
13.53
Avg Price (200 Days)
18.25
PE Ratio
17.39
EPS
0.95
Earnings Announcement
29-Jan-2025
Previous Close
14.40
Open
14.85
Day's Range
14.6 - 16.54
Year Range
12.02 - 25.95
Trading Volume
1,010,259
1 Day Change
14.72%
5 Day Change
35.41%
1 Month Change
16.34%
3 Month Change
-3.34%
6 Month Change
-18.42%
Ytd Change
-33.44%
1 Year Change
29.57%
3 Year Change
828.09%
5 Year Change
542.80%
10 Year Change
958.97%
Max Change
189.32%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.